ArticleOncoTargets and therapy2022

CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming.

Mengxuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.